The global fight against AIDS may have been destroyed by Trump

The cost of branded antiretrovirals on the basis of income, region and HIV burden has dropped by around half since 2000, according to a report. “Since 2000, pharmaceutical companies have adopted differential pricing, lowering the cost ofbranded antiretrovirals on the basis of a country’s income, region and HIV burden,” the report added. Nearly 30% of terminated NIH grants were related to HIV/AIDS.